Wall Street analyst estimates for Petros Pharmaceuticals, Inc. (PTPI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease.
Valuation Ratios
| P/E Ratio | 0.00 |
| Price / Book | 0.33 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.1M | $15.6M | $9.6M | $7.8M | $6.0M | $5.8M | $5.1M | 0 |
| Cost of Revenue | $10.5M | $12.7M | $4.0M | $1.6M | $2.3M | $1.6M | $1.2M | 0 |
| Gross Profit | $3.6M | $2.9M | $5.5M | $6.2M | $3.7M | $4.2M | $3.9M | 0 |
| Research & Development | 0 | 0 | $459636 | $1.8M | $1.7M | $2.4M | $2.6M | 0 |
| Selling, General & Admin | $11.2M | $19.7M | $15.7M | $15.6M | $12.2M | $9.3M | $8.7M | $4.6M |
| Operating Expenses | $11.2M | $25.0M | $22.8M | $24.3M | $23.6M | $17.8M | $21.6M | $4.6M |
| Operating Income | -$7.7M | -$19.3M | -$17.3M | -$18.0M | -$19.9M | -$13.6M | -$17.7M | -$4.6M |
| EBITDA | $373576 | -$14.0M | -$12.2M | -$1.7M | -$13.7M | -$4.2M | -$10.8M | -$4.5M |
| Interest Expense | 0 | $13.8M | $3.1M | $368660 | $596018 | $536138 | $560909 | 0 |
| Pre-tax Income | -$32.5M | -$33.2M | -$22.0M | -$9.0M | -$20.0M | -$8.2M | -$14.3M | -$4.5M |
| Income Tax | -$13365 | -$645866 | -$1.4M | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$32.5M | -$32.5M | -$20.6M | -$9.0M | -$20.0M | -$8.2M | -$14.3M | $1.9M |
| EPS | $-324.73 | $-132.16 | $-38.55 | $-8.25 | $-9.68 | $-6.35 | $-3.34 | $-1.56 |
| EPS (Diluted) | $-324.73 | $-132.16 | $-38.55 | $-8.25 | $-9.68 | $-6.35 | $-3.34 | $-1.56 |
| Shares Outstanding (Diluted) | $100000 | $246003 | $534068 | $1.1M | $2.1M | $2.2M | $8.0M | $280.7M |
Price
| Price | $0.01 |
| Market Cap | $0M |
| Exchange | OTC |
| Country | US |
Related companies: CCM · CELU · HEPA · IVF · LIXT · PETV · PKBO
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of PTPI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks